Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Pet Therapeutic Diet Market Size & Share 2026-2035
Report ID: GMI14191
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Pet Therapeutic Diet Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Pet Therapeutic Diet Market Size
The global pet therapeutic diet market was valued at USD 4.50 billion in 2025, is projected to reach USD 4.84 billion in 2026, and is expected to expand at a 7.7% CAGR from 2026 to 2035, reaching USD 9.47 billion by 2035.
Pet Therapeutic Diet Market Key Takeaways
Market Leader: Hill's Pet Nutrition led with over 42.2% market share in 2025.
Leading Players: Top 5 players in this market include Hill's Pet Nutrition, Mars Petcare / Royal Canin Veterinary Health Nutrition, Nestlé Purina PetCare, Virbac, Blue Buffalo (General Mills), which collectively held a market share of 97.1% in 2025.
The Pet Therapeutic Diet Market is being shaped by the convergence of chronic companion-animal conditions, more routine diagnostic workups, and owner willingness to sustain clinician-directed nutrition over extended treatment cycles. Demand is reinforced by the recurring nature of dietary management, while digital fulfillment is improving continuity after the initial veterinary recommendation.
GMI Analyst View
Based on our primary synthesis of veterinary channel procurement data and market participant consultations, the global Pet Therapeutic Diet Market reached USD 4.30 billion in 2024. This milestone underscores persistent demand momentum from chronic disease management and expanding veterinary nutrition awareness, confirming the category's resilience as a clinically mandated spending segment with limited substitution risk.
Coverage spans dry, wet/canned, semi-moist, freeze-dried, and raw/frozen therapeutic formats for dogs, cats, and other companion animals. The market excludes conventional maintenance pet food, standalone supplements and treats not classified as therapeutic diets, veterinary pharmaceuticals, livestock feed, and poultry nutrition. Gastrointestinal diets retain the largest health-condition position, while renal health and e-commerce fulfillment are becoming more influential to incremental demand.
Pet Therapeutic Diet Market Trends, Growth Drivers & GMI Forecast Outlook
Clinical nutrition is moving from a specialist adjunct toward a longer-duration component of companion-animal disease management. Chronic-condition diagnoses and digital replenishment tools are broadening access, although affordability, owner adherence, and inconsistent nutritional counseling remain material limits on conversion from clinical need to sustained therapeutic-diet use.
Key Drivers
Chronic disease creates a direct and durable prescribing mechanism for therapeutic nutrition. Nutrient modification is often sustained over the course of a condition rather than confined to a short treatment episode, making dietary management central to the commercial model for gastrointestinal, renal, metabolic, mobility, and dermatologic care. The need for repeat purchases also gives veterinary recommendation quality an outsized influence on category retention.
The distribution shift is equally consequential. Digital fulfillment does not displace the veterinarian's diagnostic role; instead, it reduces the operational friction that can interrupt a diet after it has been prescribed. This is particularly important where clinic inventory is narrow or travel burdens make replenishment inconvenient. Regulatory distinction between veterinary diets and general nutrition further supports a category in which clinical credibility, formulation discipline, and channel authorization remain central competitive assets.
Key Restraints
*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*
Nutritional counseling remains uneven within general veterinary practice. Time-constrained consultations often prioritize preventive care and acute issues, leaving body-condition assessment and dietary discussion inconsistently integrated into routine care. Without a defined diagnosis and a clear product recommendation from a trusted clinician, the category's clinical eligibility pool does not reliably become a treated consumer base.
Affordability and adherence add a second layer of restraint. Therapeutic formulations carry the cost burden of clinical development, specialized ingredients, narrower production runs, and professional-channel support. Owners may also discontinue diets when symptoms appear controlled or when follow-up reinforcement is limited. In emerging markets, the additional challenge is infrastructural: diagnosis, prescription access, and ongoing product availability must develop together before therapeutic nutrition can move beyond a small urban premium niche.
GMI Analyst View
We see the principal growth tension in the gap between animals with clinically manageable conditions and animals that actually enter sustained dietary management. The strongest opportunity lies with manufacturers that make the veterinarian's recommendation easier to initiate, refill, and explain, rather than treating product availability alone as the source of category expansion.
Pet Therapeutic Diet Market Segment Analysis
By Product Type
The Pet Therapeutic Diet Market dry food segment generated USD 2.48 billion in 2025 and represented 55.0% of global revenue. Its share is expected to be 52.0% in 2035. Dry diets remain the operating backbone of therapeutic nutrition because they offer storage efficiency, broad condition coverage, and a format that clinics and owners can manage consistently. Their modest mix moderation reflects the widening clinical use of alternative formats rather than a loss of relevance in routine long-term treatment.
Other formats, including semi-moist, freeze-dried, and raw/frozen products, held 10.0% of revenue in 2025 and are projected to grow at an 8.2% CAGR (2026–2035). These products address narrower clinical and owner-preference needs, including premium minimally processed positioning and feeding challenges associated with dental limitations or appetite suppression. Their growth reflects experimentation at the premium boundary of the category, where format innovation can differentiate offerings without replacing mainstream therapeutic platforms.
By Animal Type
The Pet Therapeutic Diet Market dog segment generated USD 2.52 billion in 2025 and is projected to reach USD 5.16 billion by 2035. Dogs retain the largest commercial base because therapeutic portfolios for canine gastrointestinal, mobility, weight, and dermatologic care are deep and well established in veterinary practice. The segment also benefits from frequent owner engagement with preventive care and a broad installed base of diet-responsive chronic conditions.
Cats represented 40.0% of market revenue in 2025 and are projected to expand at an 8.2% CAGR (2026–2035). Feline demand is increasingly shaped by the need for disease-specific management in aging animals, particularly where diet adherence can meaningfully support chronic-condition care. Product design must account for distinctive feline feeding behavior, palatability sensitivity, and the practical need for consistent intake.
Other animals accounted for 4.0% of revenue in 2025 and are expected to represent 3.5% in 2035. Clinical nutrition for small mammals and exotic companion animals remains a specialized veterinary discipline, but product development and manufacturer investment remain concentrated on dogs and cats. The segment therefore retains niche relevance without materially changing the category's species mix.
By Health Condition
The Pet Therapeutic Diet Market gastrointestinal segment generated USD 1.22 billion in 2025 and represented 27.0% of global revenue. Its share is expected to be 26.0% in 2035. Gastrointestinal diets often serve as an early entry point into therapeutic nutrition because digestive symptoms prompt veterinary consultation and can require immediate dietary adjustment. Established prescribing habits in this segment support repeat purchases and can create familiarity with condition-specific feeding among owners.
Renal health accounted for 21.0% of market revenue in 2025 and is projected to generate USD 2.13 billion by 2035. Renal nutrition is supported by the long-term nature of chronic kidney disease management and the importance of sustained feeding compliance. As veterinary practices identify disease earlier, manufacturers have an opportunity to strengthen care pathways through products that address both clinical requirements and patient acceptance.
Weight management represented 18.0% of market revenue in 2025 and is projected to generate USD 1.75 billion by 2035. The segment benefits from the visibility of obesity within routine care and from the link between excess weight and other conditions requiring veterinary intervention. Its commercial potential depends heavily on counseling quality, follow-up, and owner confidence that nutrition is producing observable outcomes.
Skin and coat diets accounted for 14.0% of revenue in 2025 and are expected to represent 13.5% in 2035. Dermatologic diets remain clinically relevant where elimination protocols, hydrolyzed proteins, or novel proteins are part of care. However, the segment faces broader competition from functional OTC claims and pharmaceutical alternatives, requiring stronger evidence communication at the point of recommendation.
Joint care generated USD 450 million in 2025 and represented 10.0% of market revenue. Its share is expected to reach 10.5% in 2035. Mobility-focused nutrition is gaining importance as companion animals live longer and veterinary care increasingly combines diet with medicines, rehabilitation, and weight control. The segment is positioned around multi-modal management rather than nutrition as a stand-alone intervention.
By Distribution Channel
Veterinary hospitals and clinics accounted for 46.0% of global revenue in 2025 and are expected to represent 40.0% in 2035. The clinic remains the primary diagnostic and prescribing authority even as fulfillment migrates toward more convenient channels. Its continuing importance rests on clinical assessment, product selection, monitoring, and the credibility of clinician-led nutritional advice.
E-commerce generated USD 1.26 billion in 2025 and is projected to grow at a 10.4% CAGR (2026–2035). Online replenishment is especially suited to therapies that must be maintained over long periods. Subscription models and prescription-validation workflows can reduce missed refills, while broader digital availability gives manufacturers access to patients beyond the inventory limits of individual clinics.
Retail pharmacies accounted for 16.0% of revenue in 2025 and are projected to generate USD 1.42 billion by 2035. Pharmacies provide an intermediate access point between veterinary practices and general retail, offering convenience while retaining a more health-oriented purchase environment. Their relevance is greatest where authorization-based dispensing and local availability can complement the initial veterinary recommendation.
Other channels accounted for 10.0% of revenue in 2025 and are expected to represent 9.0% in 2035. Pet specialty stores, supermarkets, and direct-to-consumer platforms have a limited role in a category governed by clinical authorization and disease-specific positioning. Their participation is more likely to expand through carefully controlled fulfillment and education models than through broad mass-market substitution.
GMI Analyst View
We expect product and channel innovation to reinforce each other: clinically differentiated formats can improve adherence, while digital replenishment makes that adherence easier to maintain between veterinary visits. The strategic premium will accrue to suppliers that align formulation, patient acceptance, and refill convenience around the realities of chronic care.
Pet Therapeutic Diet Market Regional Analysis
North America Pet Therapeutic Diet Market Analysis
The Pet Therapeutic Diet Market in North America represented 47.1% of global revenue in 2025 and is projected to reach USD 4.01 billion by 2035. North America's scale reflects an established prescription-diet culture, deep veterinary specialization, high pet healthcare spending, and mature access to both clinic-led and digital fulfillment. The region's commercial environment favors brands with longstanding professional trust and broad condition-specific portfolios.
U.S.
The U.S. market generated USD 1.90 billion in 2025 and is projected to reach USD 3.59 billion by 2035. The country combines advanced veterinary nutrition capabilities with a multi-channel purchasing environment that supports recurring therapeutic-diet use. Digital prescription fulfillment is particularly influential in reducing replenishment interruptions for long-duration diet protocols.
Canada
Canada accounted for 10.4% of North American revenue in 2025 and is projected to grow at a 6.8% CAGR (2026–2035). Canada's clinical infrastructure and owner spending patterns support steady adoption, although absolute scale is constrained by its smaller companion-animal population. Urban clinic concentration and professional awareness remain important supports for category development.
Europe Pet Therapeutic Diet Market Analysis
The Pet Therapeutic Diet Market in Europe generated USD 990 million in 2025 and is expected to represent 21.7% of global revenue in 2035. Europe combines sophisticated veterinary practice with country-level variation in retail structures, reimbursement practices, and owner purchasing behavior. Mature Western European markets provide dependable demand, while further expansion depends on continued clinical-nutrition adoption across a broader set of national markets.
UK
The UK generated USD 232 million in 2025 and is projected to reach USD 480 million by 2035. The country's active small-animal veterinary sector and advanced online pet-care environment support recurring diet management. Digital authorization workflows are particularly relevant to maintaining continuity once a therapeutic protocol has been initiated.
Germany
Germany accounted for 21.7% of European revenue in 2025 and is projected to generate USD 446 million by 2035. A dense veterinary network and health-conscious pet-owner base support evidence-led nutritional recommendations. The market's premium orientation gives established therapeutic brands a favorable setting for clinically differentiated products.
France
France generated USD 190 million in 2025 and is expected to represent 19.2% of European revenue in 2035. The country's organized veterinary profession and embedded manufacturer relationships support regular therapeutic-diet prescribing. Clinical education and professional-channel engagement remain central to sustaining category use.
Italy
Italy represented 14.4% of European revenue in 2025 and is projected to generate USD 294 million by 2035. Companion-animal density and growing health investment among urban households support demand, particularly through veterinary hospitals and clinics. E-commerce is widening access in larger cities but remains complementary to professional recommendation.
Spain
Spain accounted for 11.9% of European revenue in 2025 and is expected to represent 11.8% in 2035. The market benefits from an established small-animal veterinary sector, especially in metropolitan areas. Household affordability remains a meaningful constraint on conversion from diagnosis to prolonged therapeutic-diet use.
Netherlands
The Netherlands represented 9.3% of European revenue in 2025 and is projected to expand at a 7.7% CAGR (2026–2035). High digital readiness, veterinary accessibility, and strong pet-care expenditure support adoption. The country's logistics role in Northern Europe also improves its relevance as a distribution and commercial entry point for suppliers.
Asia Pacific Pet Therapeutic Diet Market Analysis
The Pet Therapeutic Diet Market in Asia Pacific accounted for 21.1% of global revenue in 2025 and is projected to grow at a 9.1% CAGR (2026–2035). Asia Pacific combines lower starting therapeutic-diet penetration with powerful structural demand drivers, including urbanization, premiumization, rising pet ownership, and expanding veterinary capacity. Growth depends on building clinical awareness and reliable access alongside consumer willingness to pay for condition-specific nutrition.
China
China represented 31.1% of Asia Pacific revenue in 2025 and is projected to generate USD 855 million by 2035. Large urban consumer markets, a growing premium pet-food culture, and investment in veterinary clinics are expanding the foundation for therapeutic diets. International brands and local clinical education initiatives are helping to translate broader pet-health awareness into prescription-nutrition demand.
Japan
Japan generated USD 230 million in 2025 and is expected to represent 20.3% of Asia Pacific revenue in 2035. Japan's mature veterinary nutrition market benefits from an older companion-animal population and developed diagnostic access. Demand is structurally supported by chronic-condition management, although demographic pressures may moderate broader population-driven expansion.
India
India generated USD 95 million in 2025 and is projected to grow at a 13.6% CAGR (2026–2035). India offers a high-growth opportunity as urban pet ownership, modern clinic networks, and veterinary education expand from a relatively early base. The pace of development will depend on distribution investment and the ability of manufacturers to establish therapeutic nutrition as a trusted clinical category.
Australia
Australia accounted for 15.8% of Asia Pacific revenue in 2025 and is projected to generate USD 265 million by 2035. The market resembles mature Western markets in its veterinary infrastructure, pet-care expenditure, and clinical nutrition awareness. Its growth profile is consequently more dependent on product mix and care intensity than on large-scale first-time market creation.
South Korea
South Korea represented 12.6% of Asia Pacific revenue in 2025 and is projected to expand at an 8.7% CAGR (2026–2035). A digitally engaged urban pet-owner base and sophisticated veterinary services support premium clinical nutrition. E-commerce is structurally important to access, making the market well suited to digitally integrated prescription and replenishment models.
Latin America Pet Therapeutic Diet Market Analysis
The Pet Therapeutic Diet Market in Latin America generated USD 275 million in 2025 and is projected to reach USD 597 million by 2035. Growth is supported by rising companion-animal ownership, expanding urban clinic networks, and increasing acceptance of premium pet nutrition. However, broad income inequality and economic volatility limit the addressable market to owners able to maintain a premium recurring diet.
Brazil
Brazil represented 57.1% of Latin American revenue in 2025 and is projected to generate USD 374 million by 2035. Brazil's sizeable companion-animal population and increasingly organized veterinary sector make it the region's central therapeutic-diet market. Urban demand and digital purchasing are creating a stronger foundation for ongoing clinical nutrition use.
Mexico
Mexico generated USD 89 million in 2025 and is projected to grow at a 7.8% CAGR (2026–2035). A growing urban middle class and broader availability of veterinary services support premium and therapeutic nutrition demand. Proximity to North American supply and brand ecosystems can improve access to established clinical product portfolios.
Argentina
Argentina accounted for 10.5% of Latin American revenue in 2025 and is expected to represent 5.9% in 2035. Macroeconomic instability creates a difficult operating environment for high-cost, recurring nutrition products. Therapeutic diets retain a role among higher-income urban owners, but affordability pressure is likely to constrain relative market development.
Middle East & Africa Pet Therapeutic Diet Market Analysis
The Pet Therapeutic Diet Market in Middle East & Africa represented 3.7% of global revenue in 2025 and is expected to account for 3.4% in 2035. Demand is concentrated in higher-income urban markets with sufficient veterinary infrastructure to support diagnosis, recommendation, and product access. Outside these centers, limited clinical capacity and lower pet-care expenditure restrict broad-based therapeutic-diet adoption.
South Africa
South Africa accounted for 37.6% of Middle East & Africa revenue in 2025 and is projected to generate USD 124 million by 2035. The country's comparatively developed veterinary sector supports therapeutic-diet use in major urban areas. It also provides a potential distribution base for suppliers seeking longer-term exposure to Southern and Eastern African markets.
Saudi Arabia
Saudi Arabia generated USD 54 million in 2025 and is projected to grow at a 7.1% CAGR (2026–2035). Growing companion-animal ownership among younger urban households and continued clinic development are broadening the base for premium veterinary nutrition. Market progress will depend on the depth and geographic reach of professional-channel infrastructure.
UAE
The UAE represented 29.7% of Middle East & Africa revenue in 2025 and is expected to represent 28.3% in 2035. High incomes, an internationally oriented pet-owning population, and developed e-commerce access support therapeutic-diet adoption. Modern veterinary networks in the major emirates provide the professional foundation for prescription-based nutrition.
GMI Analyst View
We view regional performance as a progression from mature prescription ecosystems to developing clinical-access markets. North America and Europe offer depth and continuity, while Asia Pacific offers the most consequential expansion runway; success in the latter will depend on disciplined investment in veterinary education, availability, and local channel design.
Pet Therapeutic Diet Market Share & Competitive Landscape
The Pet Therapeutic Diet Market share structure is highly concentrated, with the top five manufacturers accounting for 97.1% of global revenue in 2025. High clinical-development requirements, professional trust, formulation expertise, and veterinary-channel access create significant barriers to entry, although specialty competitors can still gain traction in discrete formats, conditions, and premium niches.
Hill's Pet Nutrition (Colgate-Palmolive)
Hill's Pet Nutrition held a 42.2% share of global market revenue in 2025. The company's competitive position rests on the breadth of its Prescription Diet portfolio, extensive veterinary relationships, and continued investment in condition-specific formulation. Its clinical positioning is reinforced by products designed for increasingly complex patient needs, enabling it to remain central to veterinarian-led diet recommendations.
Mars Petcare / Royal Canin Veterinary Health Nutrition
Mars Petcare / Royal Canin held a 36.0% share of global market revenue in 2025. Royal Canin's strength lies in its established veterinary-health platform, product specialization, and enduring professional relationships across Europe and Asia Pacific. Its scale supports broad geographic execution, while premium health-nutrition innovation helps preserve relevance as owner expectations move beyond conventional therapeutic formats.
Nestlé Purina PetCare (Pro Plan Veterinary Diets)
Nestlé Purina PetCare held a 13.3% share of global therapeutic diet revenue in 2025. Purina combines clinically credentialed condition-specific diets with expanding digital retail access. Its ability to connect veterinary nutrition research with convenient fulfillment gives the company a credible route to address the recurring purchasing requirements that define long-term therapeutic-diet management.
Virbac
Virbac competes through its Veterinary HPM range and its animal-health expertise, with a position centered on clinically differentiated nutrition delivered through veterinary professionals. The company's strategy is distinctive because it operates at the intersection of nutrition and animal health. This creates scope for solutions that address specific disease-management challenges and allows Virbac to compete on clinical utility rather than scale alone.
Blue Buffalo (General Mills), JustFoodForDogs, EmerAid, and Specialty Players
Specialty suppliers compete through fresh, critical-care, raw, freeze-dried, minimally processed, and premium clinical-nutrition adjacencies. Their ability to expand depends on meeting professional evidence expectations while offering formats or service models that larger prescription-diet manufacturers do not prioritize.
Competitive pressure is most visible at the premium edge of the market, where owner preferences for fresh feeding, specialized recovery nutrition, and digital-first access create openings for narrower portfolios. Nonetheless, sustained participation in the core therapeutic category requires clinical credibility, consistent supply, and trusted veterinarian engagement.
Recent Industry Developments
Hill's Pet Nutrition introduced new and enhanced Prescription Diet offerings at VMX in January 2025, including Multi-Organ diets for pets with concurrent systemic conditions and Brain Care + j/d formulations for cognitive dysfunction and mobility support. The company also announced ActivBiome+ upgrades for selected dermatologic and gastrointestinal products, expanding its clinical portfolio across high-demand indications [6]PR Newswire / Hill's Pet Nutrition. “Hill's Pet Nutrition Leads the Way in Microbiome Science at VMX 2025, Unveiling Breakthrough Product Innovations.” prnewswire.com.
Virbac launched Vikaly in Europe in September 2025, describing it as the first medicated feed for cats. The product combines a renal diet with benazepril for the management of proteinuria associated with feline chronic kidney disease, integrating dietary and pharmaceutical management in a prescription-dispensed format [7]Virbac. “Virbac Introduces World-First Medicated Feed for Cats.” virbac.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →